CPAP Therapy and Atrial Fibrillation Recurrence in OSA

Effects of CPAP Therapy on Atrial Fibrillation Recurrence in Patients With Obstructive Sleep Apnea: A Prospective Cohort Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07358429

Acronym

CPAP-AF

Enrollment

Registered

2026-01-22

Start date

2024-09-01

Completion date

2027-12-30

Last updated

2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation (Paroxysmal), Obstructive Sleep Apnea (OSA)

Keywords

sleep apnea, atrial fibrillation, CPAP therapy

Brief summary

Obstructive sleep apnea (OSA) is a major modifiable risk factor for atrial fibrillation (AF). Continuous positive airway pressure (CPAP) therapy has been shown to improve cardiovascular outcomes; however, real-world data on its effect on AF recurrence remain limited. This prospective cohort study aims to evaluate the association between objective CPAP adherence and the risk of AF recurrence in patients with moderate-to-severe OSA and a history of paroxysmal AF. Patients will be followed for 12 months, with AF recurrence assessed using electrocardiography and Holter monitoring.

Detailed description

This is a prospective, real-world cohort study enrolling adult patients with moderate-to-severe obstructive sleep apnea (AHI ≥ 15 events/hour) and documented paroxysmal atrial fibrillation. OSA is diagnosed using home sleep apnea testing. All participants initiate CPAP therapy, with objective adherence data collected via telemonitoring. Patients are followed for 12 months to assess AF recurrence, progression to permanent AF, and associations with CPAP usage metrics.

Interventions

DEVICEContinuous Positive Airway Pressure (CPAP)

CPAP therapy is initiated according to standard clinical practice. Objective adherence data (mean nightly usage, percentage of nights ≥ 4 hours) are collected via telemonitoring systems.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age ≥ 18 years 2. Diagnosed moderate-to-severe OSA 3. History of paroxysmal atrial fibrillation 4. Ability to initiate CPAP therapy 5. Written informed consent -

Exclusion criteria

1. Left ventricular ejection fraction \< 50% 2. Permanent atrial fibrillation 3. Central sleep apnea 4. End-stage chronic kidney disease 5. Inability to obtain or tolerate CPAP therapy -

Design outcomes

Primary

Measure	Time frame	Description
Time to First Recurrence of Paroxysmal Atrial Fibrillation	12 months	First documented recurrence of paroxysmal AF confirmed by 12-lead ECG or 24-hour Holter monitoring.

Secondary

Measure	Time frame	Description
Progression to Permanent Atrial Fibrillation	12 months	Progression to Permanent Atrial Fibrillation for 12 months

Countries

Bulgaria

Contacts

PRINCIPAL_INVESTIGATORPetar R Kalaydzhiev, PhD

Medical University - Sofia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026